Evidence map›Paper›PMID 40221807›Full record

SynthesisStem cell research & therapy2025

The inconclusive superiority debate of allogeneic versus autologous MSCs in treating patients with HFrEF: a systematic review and meta-analysis of RCTs.

Omar T F Ahmed, Ziyad Tarek Ahmed, Abdulrahman W Dairi, Maha Saad Zain Al-Abeden, Mohammed H Alkahlot, Rana H Alkahlot, Ghazi I Al Jowf, Lars M T Eijssen, Khawaja Husnain Haider

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Omar T F AhmedCollege of Medicine, Sulaiman Alrajhi University, 52726, Al-Bukairiyah, Saudi Arabia.ORCID https://orcid.org/0009-0003-2116-8048
Ziyad Tarek AhmedCollege of Medicine, Sulaiman Alrajhi University, 52726, Al-Bukairiyah, Saudi Arabia.ORCID https://orcid.org/0000-0001-6737-0194
Abdulrahman W DairiCollege of Medicine, Sulaiman Alrajhi University, 52726, Al-Bukairiyah, Saudi Arabia.
Maha Saad Zain Al-AbedenCollege of Medicine, Sulaiman Alrajhi University, 52726, Al-Bukairiyah, Saudi Arabia.ORCID https://orcid.org/0009-0008-5634-8432
Mohammed H AlkahlotCollege of Medicine, Sulaiman Alrajhi University, 52726, Al-Bukairiyah, Saudi Arabia.ORCID https://orcid.org/0009-0009-3849-2315
Rana H AlkahlotCollege of Medicine, Sulaiman Alrajhi University, 52726, Al-Bukairiyah, Saudi Arabia.
Ghazi I Al JowfDepartment of Public Health, College of Applied Medical Sciences, King Faisal University, 31982, Al-Ahsa, Saudi Arabia.ORCID https://orcid.org/0000-0002-9414-4309
Lars M T EijssenDepartment of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences, Maastricht University Medical Centre, 6200 MD, Maastricht, The Netherlands.ORCID https://orcid.org/0000-0002-6473-2839
Khawaja Husnain HaiderCollege of Medicine, Sulaiman Alrajhi University, 52726, Al-Bukairiyah, Saudi Arabia. kh.haider@sr.edu.sa.ORCID http://orcid.org/0000-0002-7907-4808

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent randomized controlled trials have consistently demonstrated the safety and potential efficacy of MSC therapy for heart failure patients. This study delves into mesenchymal stem cells' promising potential, offering a beacon of hope for the future of heart failure treatment with reduced ejection fraction (HFrEF).

methodsWe followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for this systematic review and meta-analysis. We searched four databases and registers for RCTs, including PubMed, EBSCO, clinicaltrials.gov, ICTRP, and other relevant websites. We then selected thirteen RCTs with 1184 participants based on our pre-defined inclusion/exclusion criteria. Two independent assessors extracted the data and performed a quality assessment. The data were then plotted for various outcomes, including death, hospitalization, major adverse cardiac events, pump function parameters, and 6-min walk distance.

resultsThe safety of MSC-based treatment has been consistently demonstrated with MSCs from autologous (

conclusionOur findings suggest that

Indexed as

Heart FailureMesenchymal Stem CellsMesenchymal Stem Cell TransplantationHumansRandomized Controlled Trials as TopicStroke VolumeTransplantation, AutologousTransplantation, HomologousAllogeneicAutologousHeart failureHFrEFMesenchymal precursor cellsMesenchymal stem cellsRCTs

Identifiers

PMID40221807
PMCPMC11993956

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.